Doxorubicin-loaded NK exosomes enable cytotoxicity against triple-negative breast cancer spheroids

سال انتشار: 1403
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 96

فایل این مقاله در 12 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJBMS-27-12_013

تاریخ نمایه سازی: 13 آبان 1403

چکیده مقاله:

Objective(s): Natural killer (NK) cells are the most professional innate immune cells that initiate extracellular apoptosis via cytotoxic granules in malignant cells. Antitumoral properties of NK-derived exosomes (Exos) are attributed to their parent cells. Loading drugs into Exos as a carrier can enhance their effect and enable targeted delivery. In the present study, we aim to deliver Doxorubicin (DOX) to the breast cancer spheroids by NK-Exos.Materials and Methods: Peripheral blood mononuclear cells (PBMC) were used to harvest NK cells, and NK-Exos were isolated from NK cell expansion medium using an Exo-spinTM kit. DOX was loaded via the ultrasonication method. AO/EtBr, Annexin/PI, DAPI, MTT, and spheroids of human breast cancer were used to track the cytotoxic effect of DOX-NK-Exos. The colony formation assay, scratch and transwell assays, Real-Time PCR for p۵۳ and VEGF-A, and WB for protein expression were also performed.Results: When compared to free DOX, all viability tests validated the inhibitory effects of DOX-NK-Exos. The obtained results indicated that DOX-NK-Exos selectively reduced tumor cell viability and spared fibroblast and MCF-۱۰A as noncancerous cells. Long after spheroid treatment, DOX-NK-Exos’ remarkable effect persisted.Conclusion: Human breast carcinoma mass treated with DOX-NK-Exos underwent apoptosis and showed a strong inhibitory effect on proliferation. Thus, they can reduce the side effects of chemotherapeutics and can be used as drug carriers with selective toxicity. Additionally, the additive action of this combination formula results in a more severe loss in cell viability.

نویسندگان

Zahra Sadat Hashemi

ATMP Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran

Mahlegha Ghavami

Pathology Department, Dalhousie University, Halifax, Canada

Fateme Mohammadi

Department of Hematology, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran

Mahdieh Shokrollahi Barough

ATMP Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran

Farhad Shokati

Biomaterials and Tissue Engineering Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran

Saber Asghari

ATMP Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran

saeed khalili

Department of Biology Sciences, Shahid Rajaee Teacher Training University, Tehran, Iran

Mandana Akbari Yekta

Biomaterials and Tissue Engineering Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran

Ardeshir Ghavamzadeh

Cancer and Cell Therapy Research Center, Tehran University of Medical Sciences, Tehran, Iran

Ramin Sarrami Forooshani

ATMP Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Yang F, Teves SS, Kemp CJ, Henikoff S. Doxorubicin, DNA ...
  • Tian Y, Li S, Song J, Ji T, Zhu M, ...
  • Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. New ...
  • Tung NM, Winer EP. Tumor-infiltrating lymphocytes and response to platinum ...
  • Cancello G, Bagnardi V, Sangalli C, Montagna E, Dellapasqua S, ...
  • Torrisi R, Balduzzi A, Ghisini R, Rocca A, Bottiglieri L, ...
  • Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: Drug ...
  • Hashemi ZS, Ghavami M, Kashyap MK. Exosomes, miRNAs, and lncRNAs ...
  • Johnsen KB, Gudbergsson JM, Skov MN, Pilgaard L, Moos T, ...
  • Fath MK, Naderi M, Hamzavi H, Ganji M, Shabani S, ...
  • Kooijmans S, Fliervoet L, Van Der Meel R, Fens M, ...
  • Schindler C, Collinson A, Matthews C, Pointon A, Jenkinson L, ...
  • Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, ...
  • Gong C, Tian J, Wang Z, Gao Y, Wu X, ...
  • Hatami Z, Hashemi ZS, Eftekhary M, Amiri A, Karpisheh V, ...
  • Kumar DN, Chaudhuri A, Aqil F, Dehari D, Munagala R, ...
  • Gomari H, Moghadam MF, Soleimani M, Ghavami M, Khodashenas S. ...
  • Parvin D, Hashemi ZS, Shokati F, Mohammadpour Z, Bazargan V. ...
  • Ryan S-L, Baird A-M, Vaz G, Urquhart AJ, Senge h, ...
  • Hashemi ZS, Moghadam MF, Soleimani M. Comparison of the ex ...
  • Hashemi ZS, Moghadam MF, Soleimani M, Hafizi M, Amirizadeh N. ...
  • Goodman TT, Ng CP, Pun SH. ۳-D tissue culture systems ...
  • Ramamoorthy P, Thomas SM, Kaushik G, Subramaniam D, Chastain KM, ...
  • Bordanaba-Florit G, Madarieta I, Olalde B, Falcón-Pérez JM, Royo F. ...
  • Shimasaki N, Coustan-Smith E, Kamiya T, Campana D. Expanded and ...
  • Mohammadi F, Hashemi ZS, Forooshani RS, Alizadeh S. Bioactivity of ...
  • Chen X, Han J, Chu J, Zhang L, Zhang J, ...
  • Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, ...
  • Lugini L, Cecchetti S, Huber V, Luciani F, Macchia G, ...
  • Zhu L, Kalimuthu S, Gangadaran P, Oh JM, Lee HW, ...
  • Zhu L, Oh JM, Gangadaran P, Kalimuthu S, Baek SH, ...
  • Ahmadvand M, Barough MS, Hashemi ZS, Sanati H, Abbasvandi F, ...
  • Hashemi ZS, Ghavami M, Kiaie SH, Mohammadi F, Barough MS, ...
  • Hashemi ZS, Moghadam MF, Khalili S, Ghavami M, Salimi F, ...
  • Hashemi ZS, Forouzandeh Moghadam M, Soleimani M. Comparison of TGFbR۲ ...
  • Hashemi ZS, Moghadam MF, Sadroddiny E. Varying miR-۱۹۳b-۳p expression patterns ...
  • Hashemi ZS, Moghadam MF, Farokhimanesh S, Rajabibazl M, Sadroddiny E. ...
  • Imamura Y, Mukohara T, Shimono Y, Funakoshi Y, Chayahara N, ...
  • Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification ...
  • Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, ...
  • Han D, Wang K, Zhang T, Gao G, Xu H. ...
  • Wu F, Xie M, Hun M, She Z, Li C, ...
  • Neviani P, Wise PM, Murtadha M, Liu CW, Wu C-H, ...
  • Choi J-W, Lim S, Kang JH, Hwang SH, Hwang K-C, ...
  • Federici C, Shahaj E, Cecchetti S, Camerini S, Casella M, ...
  • Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, ...
  • Mutlu EC, Kaya Ö, Wood M, Mager I, Topkara KÇ, ...
  • Chen P, Wang Z, Zong S, Zhu D, Chen H, ...
  • Iessi E, Logozzi M, Lugini L, Azzarito T, Federici C, ...
  • Wei H, Chen J, Wang S, Fu F, Zhu X, ...
  • Cui X, Hartanto Y, Zhang H. Advances in multicellular spheroids ...
  • Chen L, Brigstock DR. Integrins and heparan sulfate proteoglycans on ...
  • Zhu R, Wang Z, Liang P, He X, Zhuang X, ...
  • Guerriero E, Sorice A, Capone F, Storti G, Colonna G, ...
  • Hamadneh L, Abu-Irmaileh B, Al-Majawleh M, Bustanji Y, Jarrar Y, ...
  • Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer ...
  • Srivastava A, Amreddy N, Babu A, Panneerselvam J, Mehta M, ...
  • Toffoli G, Hadla M, Corona G, Caligiuri I, Palazzolo S, ...
  • نمایش کامل مراجع